An Activist Investor Takes On BlackRock Over E.S.G. - The New York Times
New GSK Takes Flight With Strong Quarter, Forecast Boost
Activist Bluebell takes stake in GlaxoSmithKline to push for change at top
GlaxoSmithKline chairman Jonathan Symonds accuses activist Bluebell of distortion in bid to oust Emma Walmsley
Punchy Bluebell an unlikely ally to US giant in Glaxo stand-off
Small but formidable activist investor Bluebell takes stake in GlaxoSmithKline, asks CEO Walmsley to reapply for job: FT
Emma Walmsley Fierce Pharma
Alan Jope Unilever: GSK rejects $68b Unilever bid for consumer healthcare unit, ET BrandEquity
Second hedge fund pushes for change in leadership of GSK, GlaxoSmithKline